The consensus price target hints at a 42.8% upside potential for Pulmonx Corporation (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
REDWOOD CITY, Calif., September 21, 2021--Pulmonx Announces BCBS of Michigan and Horizon BCBS of New Jersey Issue Coverage Policies Providing Coverage for Treatment with the Zephyr® Valve
Stocks of biotech companies fighting COVID-19 have been great investments over the last two years. What stocks might zoom higher when the pandemic is over?